A phase II/III trial of gastroretentive, sustained release zinc-monocysteine in patients with amyotrophic lateral sclerosis.

Next Previous
Trial Profile

A phase II/III trial of gastroretentive, sustained release zinc-monocysteine in patients with amyotrophic lateral sclerosis.

Planning
Phase of Trial: Phase II/III

Latest Information Update: 02 Dec 2011

At a glance

  • Drugs Riluzole; Zinc monocysteine
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top